Julia Etchin, Ph.D. - Publications

Yale University, New Haven, CT 
DNA Repair

23 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Prutsch N, Jing C, Etchin J, Berezovskaya A, Tiv H, Poitras MJ, Gokhale P, Landesman Y, Look AT. Abstract 2953: Selective activity of XPO1 inhibitors in TET2-mutant myeloid malignancies Cancer Research. 79: 2953-2953. DOI: 10.1158/1538-7445.Am2019-2953  0.403
2017 Akahane K, Li Z, Etchin J, Berezovskaya A, Gjini E, Masse CE, Miao W, Rocnik J, Kapeller R, Greenwood JR, Tiv H, Sanda T, Weinstock DM, Look AT. Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia. British Journal of Haematology. PMID 28295194 DOI: 10.1182/Blood.V128.22.1596.1596  0.423
2017 Abraham BJ, Hnisz D, Weintraub AS, Kwiatkowski N, Li CH, Li Z, Weichert-Leahey N, Rahman S, Liu Y, Etchin J, Li B, Shen S, Lee TI, Zhang J, Look AT, et al. Small genomic insertions form enhancers that misregulate oncogenes. Nature Communications. 8: 14385. PMID 28181482 DOI: 10.1038/Ncomms14385  0.336
2017 Etchin J, Berezovskaya A, Conway AS, Galinsky IA, Stone RM, Baloglu E, Senapedis W, Landesman Y, Kauffman M, Shacham S, Wang JC, Look AT. Abstract 39: XPO1 inhibitor, KPT-8602, is well tolerated and highly active against AML blasts and LICs Clinical Cancer Research. 23: 39-39. DOI: 10.1158/1557-3265.Hemmal17-39  0.472
2016 Etchin J, Berezovskaya A, Conway AS, Galinsky IA, Stone RM, Baloglu E, Senapedis W, Landesman Y, Kauffman M, Shacham S, Wang JC, Look AT. KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells. Leukemia. PMID 27211268 DOI: 10.1038/Leu.2016.145  0.476
2016 Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, ... ... Etchin J, et al. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 29: 574-86. PMID 27070704 DOI: 10.1016/J.Ccell.2016.03.008  0.385
2015 Etchin J, Montero J, Berezovskaya A, Le BT, Kentsis A, Christie AL, Conway AS, Chen WC, Reed C, Mansour MR, Ng CE, Adamia S, Rodig SJ, Galinsky IA, Stone RM, et al. Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-Initiating cells engrafted into immunosuppressed NSG mice. Leukemia. PMID 26202935 DOI: 10.1038/Leu.2015.194  0.465
2015 Etchin J, Berezovskaya A, Saur Conway A, Chen WC, Baloglu E, Landesman Y, Senapedis W, Ellis J, McCauley D, Stone RM, Galinsky I, DeAngelo DJ, Kauffman M, Shacham S, Wang JC, et al. Nuclear Export Inhibitor KPT-8602 Is Highly Active Against Leukemic Blasts and Leukemia-Initiating Cells in Patient-Derived Xenograft Models of AML Blood. 126: 326-326. DOI: 10.1182/Blood.V126.23.326.326  0.477
2015 Murakami MA, Christodoulou AN, Christie AL, DeSouza T, Louissaint A, Vojinovic U, Koch R, Li LS, Kallgren SP, Rao P, Köster J, Vadhi R, Duberow E, Morgan EA, Wang H, ... ... Etchin J, et al. Proxe: A Public Repository of Xenografts to Facilitate Studies of Biology and Expedite Preclinical Drug Development in Leukemia and Lymphoma Blood. 126: 3252-3252. DOI: 10.1182/Blood.V126.23.3252.3252  0.413
2015 Etchin J, Le BT, Berezovskaya A, Conway AS, Chen WC, Kentsis A, Mansour MR, Stone RM, Galinsky IA, DeAngelo DJ, McCauley D, Kauffman M, Shacham S, Wang JC, Kung AL, et al. Abstract 4445: Selective inhibitor of nuclear exporter CRM1/XPO1, Selinexor (KPT-330), exhibits remarkable activity against AML leukemia-initiating cells while sparing normal hematopoietic cells Cancer Research. 75: 4445-4445. DOI: 10.1158/1538-7445.Am2015-4445  0.516
2014 Mansour MR, Abraham BJ, Anders L, Berezovskaya A, Gutierrez A, Durbin AD, Etchin J, Lawton L, Sallan SE, Silverman LB, Loh ML, Hunger SP, Sanda T, Young RA, Look AT. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science (New York, N.Y.). 346: 1373-7. PMID 25394790 DOI: 10.1126/Science.1259037  0.385
2014 Barceló C, Etchin J, Mansour MR, Sanda T, Ginesta MM, Sanchez-Arévalo Lobo VJ, Real FX, Capellà G, Estanyol JM, Jaumot M, Look AT, Agell N. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells. Gastroenterology. 147: 882-892.e8. PMID 24998203 DOI: 10.1053/J.Gastro.2014.06.041  0.331
2014 Etchin J, Le BT, Kentsis A, Mansour MR, Berezovskaya A, Stone RM, Galinsky I, DeAngelo DJ, McCauley D, Kauffman M, Shacham S, Wang JCY, Kung AL, Look AT. ­Selective Inhibitor of Nuclear Export (SINE), Selinexor (KPT-330), Shows Remarkable Activity Against AML Leukemia-Initiating Cells Blood. 124: 995-995. DOI: 10.1182/Blood.V124.21.995.995  0.449
2013 Etchin J, Sanda T, Mansour MR, Kentsis A, Montero J, Le BT, Christie AL, McCauley D, Rodig SJ, Kauffman M, Shacham S, Stone R, Letai A, Kung AL, Thomas Look A. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. British Journal of Haematology. 161: 117-27. PMID 23373539 DOI: 10.1111/Bjh.12231  0.479
2013 Etchin J, Sun Q, Kentsis A, Farmer A, Zhang ZC, Sanda T, Mansour MR, Barcelo C, McCauley D, Kauffman M, Shacham S, Christie AL, Kung AL, Rodig SJ, Chook YM, et al. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia. 27: 66-74. PMID 22847027 DOI: 10.1038/Leu.2012.219  0.445
2013 Etchin J, Le BT, Kentsis A, Stone RM, McCauley D, Kauffman M, Shacham S, Wang JCY, Kung AL, Look AT. Novel Inhibitors Of CRM1/XPO1 Nuclear Exporter Exhibit Striking Activity Against AML “primagrafts,” Including AML Leukemia Initiating Cells, While Sparing Normal Hematopoietic Cells Blood. 122: 3932-3932. DOI: 10.1182/Blood.V122.21.3932.3932  0.502
2013 Akahane K, Sanda T, Mansour MR, Etchin J, Cherry N, Weinstock DM, Letai A, DeAngelo DJ, Look AT. HSP90 Inhibition Has Potent Activity Against T-Cell Acute Lymphoblastic Leukemia (T-ALL) Through Degradation Of TYK2 Kinase Blood. 122: 2528-2528. DOI: 10.1182/Blood.V122.21.2528.2528  0.434
2012 Etchin J, Kentsis A, Sanda T, Kung AL, Stone RM, McCauley D, Kauffman M, Shacham S, Look AT. Evaluation of KPT-SINE (Selective Inhibitors of CRM1-Mediated Nuclear Export) in AML and T-ALL. Journal of Clinical Oncology. 30: e13586-e13586. DOI: 10.1200/Jco.2012.30.15_Suppl.E13586  0.485
2011 Etchin J, Kanki JP, Look AT. Zebrafish as a model for the study of human cancer. Methods in Cell Biology. 105: 309-37. PMID 21951536 DOI: 10.1016/B978-0-12-381320-6.00013-8  0.313
2011 Etchin J, Kentsis A, Sanda T, Kung AL, Stone RM, McCauley D, Kauffman M, Shacham S, Look T. KPT-SINE, a Potent, Small Molecule Inhibitor of CRM1-Dependent Nuclear-Cytoplasmic Shuttling, with Potent Activity Against T-ALL and AML Blood. 118: 2622-2622. DOI: 10.1182/Blood.V118.21.2622.2622  0.482
2010 Dray E, Etchin J, Wiese C, Saro D, Williams GJ, Hammel M, Yu X, Galkin VE, Liu D, Tsai MS, Sy SM, Schild D, Egelman E, Chen J, Sung P. Enhancement of RAD51 recombinase activity by the tumor suppressor PALB2. Nature Structural & Molecular Biology. 17: 1255-9. PMID 20871616 DOI: 10.1038/Nsmb.1916  0.472
2010 Gutierrez A, Kentsis A, Sanda T, Etchin J, Protopopov A, Zhang J, Chin L, Silverman LB, Winter S, Hunger S, Sallan SE, Zha S, Alt F, Look AT. The BCL11B Tumor Suppressor Is Mutated In Human T-Cell Acute Lymphoblastic Leukemia Blood. 116: 4177-4177. DOI: 10.1182/Blood.V116.21.4177.4177  0.414
2006 San Filippo J, Chi P, Sehorn MG, Etchin J, Krejci L, Sung P. Recombination mediator and Rad51 targeting activities of a human BRCA2 polypeptide. The Journal of Biological Chemistry. 281: 11649-57. PMID 16513631 DOI: 10.1074/Jbc.M601249200  0.456
Show low-probability matches.